Thalomid

(thalidomide)

ApprovedSmall molecule

Thalidomide is used to treat multiple myeloma (a type of blood cancer) and a skin condition called erythema nodosum leprosum that can occur in leprosy patients. It works by helping the immune system fight cancer cells and reducing inflammation.[2] Thalomid is currently approved and in use across 62 indications[4].[1]

Thalomid is one of 927 small molecule programs targeting Multiple Myeloma. It is currently in Approved.

Indications

311

Total Trials

Active Trials

926

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Multiple MyelomaUnknown status

MyelofibrosisCompleted

Autoimmune DiseaseActive, not recruiting

Congestive Heart FailureActive, not recruiting

Efficacy and SafetyCompleted

Immune System DiseaseActive, not recruiting

ParagangliomaApproved

Malignant Epithelial Tumor of OvaryApproved

Primary MyelofibrosisApproved

Colorectal AdenocarcinomaApproved

Multiple MyelomaApproved

Unknown status

MyelofibrosisPhase 2

Completed

Autoimmune DiseaseApproved

Active, not recruiting

Congestive Heart FailureApproved

Active, not recruiting

Efficacy and SafetyPhase 2

Completed

Immune System DiseaseApproved

Active, not recruiting

ParagangliomaApproved

Approved

Malignant Epithelial Tumor of OvaryApproved

Approved

Primary MyelofibrosisApproved

Approved

Colorectal AdenocarcinomaApproved

Approved

Showing 10 of 59 indications

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

67 2

Fludara

Sanofi

Phase 3

47 3

Keytruda

Merck & Co.

Phase 3

17 4

Biaxin

AbbVie

Phase 3

15 5

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 6

Treanda

AAzurity Pharmaceuticals

Phase 3

19 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 8

Linvoseltamab

Regeneron

Phase 3

10 9

Etentamig

AbbVie

Phase 3

8 10

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Injury

NCT06617182

Phase 3Recruiting

Nausea and Vomiting

NCT06017284

Phase 2Active, not recruiting

Trial

NCT00871013

Recruiting

Study completion

NCT06382519

Q1 2027

Phase 2Active, not recruiting

Myelofibrosis

NCT03069326

Q2 2027

Phase 2Recruiting

Efficacy and Safety

NCT07187193

Clinical

Trials by Indication[1]

Multiple Myeloma46 trials

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Completed·—·Phase 2·NCT00004088·77 enrolled

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00966693·77 enrolled

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT01057225·64 enrolled

Show 43 more trials

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00657488·400 enrolled

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00458705·45 enrolled

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

Completed·UUniversity of Arkansas·Phase 3·NCT00083876·500 enrolled

Thalidomide for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038233·27 enrolled

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00452569·499 enrolled

Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma

Completed·UUniversity of Arkansas·Phase 2·NCT00083577·250 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

CURATE.AI Optimized Modulation for Multiple Myeloma

Unknown status·NNational University Hospital, Singapore·Phase 2/3·NCT03759093·20 enrolled

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Completed·MMayo Clinic·Phase 3·NCT00432458·68 enrolled

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00006890·67 enrolled

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT02410694·90 enrolled

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

Completed·UUniversità Politecnica delle Marche·Phase 3·NCT00633542·103 enrolled

Study of Combination PS-341 and Thalidomide in Multiple Myeloma

Completed·UUniversity of Arkansas·Phase 1·NCT00083460·86 enrolled

THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)

Completed·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 2·NCT01341262·378 enrolled

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT02891811·124 enrolled

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00075829·710 enrolled

Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

Terminated·—·Phase 3·NCT00644306·232 enrolled

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00008242

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00287872·30 enrolled

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 1·NCT01537861·7 enrolled

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00033332

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00124579·7 enrolled

The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy

Unknown status·WWuhan University·Phase 1·NCT02467647·500 enrolled

STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Completed·MMario Boccadoro·Phase 2·NCT02586038·175 enrolled

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00049673·332 enrolled

Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

Completed·UUniversity Hospital, Lille·Phase 3·NCT00367185·500 enrolled

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·—·Phase 2·NCT00792142·45 enrolled

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Unknown status·PProf Jamie Cavenagh·Phase 1/2·NCT02145715·54 enrolled

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma

Unknown status·JJinling Hospital, China·Phase 3·NCT02248428·130 enrolled

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00523848·46 enrolled

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

Withdrawn· Takeda logo

Takeda·Phase 2·NCT03608501

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00097981·225 enrolled

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn·TThe Cleveland Clinic·Phase 2·NCT00112879

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00182663·30 enrolled

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

Unknown status·UUniversity Hospital, Bonn·Phase 2·NCT00124813·80 enrolled

Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

Completed·UUniversity of Turin, Italy·Phase 2·NCT00358020·30 enrolled

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

Completed·PPETHEMA Foundation·Phase 4·NCT00652041·40 enrolled

Thalidomide-Dexamethasone for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT00038090·83 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005834·19 enrolled

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00049374

Hepatocellular Carcinoma7 trials

Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

Unknown status·SSun Yat-sen University·Phase 2/3·NCT00728078·200 enrolled

Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma

Unknown status·NNational Taiwan University Hospital·Phase 1/2·NCT00155272·19 enrolled

UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma

Completed·NNational Taiwan University Hospital·Phase 2·NCT00519688·44 enrolled

Show 4 more trials

A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT07309419·222 enrolled

Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma

Unknown status·FFudan University·Phase 3·NCT00921531·200 enrolled

Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma

Unknown status·TThe First Affiliated Hospital of Xiamen University·N/A·NCT01924624·140 enrolled

Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

Terminated·TTTY Biopharm·Phase 3·NCT00225290·230 enrolled

Dexamethasone5 trials

High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP

Withdrawn·SShandong University·Phase 2·NCT01976195

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

Completed·UUniversity of Arkansas·Phase 3·NCT00083915·97 enrolled

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Completed· Takeda logo

Takeda·Phase 3·NCT00507416·502 enrolled

Show 2 more trials

Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy

Completed·UUniversity of Arkansas·Phase 2·NCT00083902·190 enrolled

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Unknown status·LLi Zheng·Phase 1/2·NCT04891744·48 enrolled

Lymphoma4 trials

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Unknown status·HHuiqiang Huang·Phase 3·NCT02085655·264 enrolled

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00015912·35 enrolled

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT02733380·20 enrolled

Show 1 more trial

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00022581·45 enrolled

Thalassemia4 trials

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

Completed·MMuhammad Aamir Latif·N/A·NCT06888232·121 enrolled

Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial

Recruiting·—·Phase 4·NCT06299670·90 enrolled

Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia

Completed·—·Phase 1·NCT06098014·60 enrolled

Show 1 more trial

Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.

Completed·NNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan·Phase 2·NCT06239389·24 enrolled

98 more indications

Prostate Cancer4 trials

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

Completed·TThe Cleveland Clinic·Phase 2·NCT00400517·28 enrolled

A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001446·64 enrolled

An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT00201357·30 enrolled

Show 1 more trial

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy

Completed·NNuvance Health·Phase 2·NCT00046826

Vascular Malformation4 trials

Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding

Withdrawn·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02754960

Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT00964496·55 enrolled

Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment

Withdrawn·ZZhizheng Ge·Phase 2·NCT02301949

Show 1 more trial

the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT02707484·150 enrolled

Liver Cancer3 trials

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

Completed·—·Phase 2·NCT00058487·12 enrolled

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006016·75 enrolled

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006006·38 enrolled

Metastatic Melanoma3 trials

Thalidomide and Dacarbazine for Metastatic Melanoma

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006200

Biochemotherapy With Temozolomide for Metastatic Melanoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505635·5 enrolled

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00017316·35 enrolled

Non-Small Cell Lung Cancer3 trials

Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00025285·46 enrolled

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00281827·22 enrolled

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00004859·589 enrolled

Efficacy and Safety3 trials

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

Unknown status·YYunpeng Liu·N/A·NCT03601871·880 enrolled

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

Recruiting·—·Phase 2·NCT07187193·50 enrolled

Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome

Not yet recruiting·WWenjie Zheng·N/A·NCT07476625·106 enrolled

Metastatic Colorectal Cancer2 trials

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05266820·120 enrolled

Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00019747·39 enrolled

Glioma2 trials

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00412542·78 enrolled

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00047879·7 enrolled

Waldenstrom macroglobulinemia2 trials

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01779167·4 enrolled

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00723658

Patients With Advanced Solid Tumors2 trials

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00062127·35 enrolled

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

Unknown status·HHaihe Biopharma Co., Ltd.·Phase 1·NCT02870036·243 enrolled

Idiopathic Pulmonary Fibrosis2 trials

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

Completed·JJohns Hopkins University·Phase 2·NCT00162760·19 enrolled

Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Completed·JJohns Hopkins University·Phase 3·NCT00600028·25 enrolled

Radiation Therapy2 trials

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00033254·332 enrolled

Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

Completed·WWake Forest University Health Sciences·Phase 2·NCT00049361

Maintenance Therapy2 trials

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02844309·44 enrolled

Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

Completed·UUniversity of Miami·Phase 2·NCT02507336·2 enrolled

Crohn's Disease2 trials

Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors

Terminated·IIRCCS Burlo Garofolo·Phase 3·NCT03221166·9 enrolled

Thalidomide in Treating Crohn's Disease

Completed·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT02501291·47 enrolled

Mantle Cell Lymphoma2 trials

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Myelofibrosis2 trials

Thalidomide in Treating Patients With Myelofibrosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00015821·43 enrolled

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03069326·30 enrolled

Beta-Thalassemia2 trials

Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients

Completed·BBlood Care Clinic·Phase 3·NCT06146478·200 enrolled

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Recruiting·NNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan·Phase 2·NCT06490627·54 enrolled

HIV wasting syndrome2 trials

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002157

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00002127·75 enrolled

Myelodysplastic Syndrome2 trials

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00015990·29 enrolled

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00030550

Chronic Lymphocytic Leukemia2 trials

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT00096018·43 enrolled

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006226·41 enrolled

Macroglobulinemia2 trials

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

Completed·UUniversity of Arkansas·Phase 2·NCT00083707·40 enrolled

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT00142116·25 enrolled

Primary Systemic Amyloidosis2 trials

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Completed·SSWOG Cancer Research Network·Phase 2·NCT00064337·104 enrolled

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089167

Myelodysplastic Syndromes2 trials

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00050843·220 enrolled

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Completed·GGroupe Francophone des Myelodysplasies·Phase 2·NCT00455910·112 enrolled

Plasma Cell Leukemia1 trial

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00258245·5 enrolled

Nausea and vomiting1 trial

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Recruiting·FFudan University·Phase 3·NCT06017284·100 enrolled

Cirrhosis1 trial

Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06772480·100 enrolled

NSCLC1 trial

Conmana Combined With Thalidomide to Treat NSCLC

Unknown status·HHenan Provincial People's Hospital·Phase 4·NCT02778893·67 enrolled

Unknown status·—·Phase 2·NCT01551641·180 enrolled

Safety and Efficacy1 trial

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

Completed·—·Phase 1·NCT00002104

Soft Tissue Sarcoma1 trial

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00089544·23 enrolled

Malnutrition1 trial

Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients

Withdrawn·—·Phase 4·NCT00390247

Transplantation1 trial

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Terminated·UUniversity of Iowa·Phase 2·NCT01548573·19 enrolled

Venous malformation1 trial

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

Completed·—·Phase 2·NCT00389935·14 enrolled

Advanced NSCLC1 trial

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Unknown status·QQilu Hospital of Shandong University·Phase 2·NCT03062800·232 enrolled

Proctitis1 trial

Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT04680195·62 enrolled

Recurrent1 trial

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025220·60 enrolled

Amyloidosis1 trial

Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis

Unknown status·SSeoul National University Hospital·Phase 2·NCT02966522·30 enrolled

Ovarian Reserve1 trial

Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT02998827·90 enrolled

Carcinosarcoma1 trial

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025506·55 enrolled

Angiogenesis1 trial

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Completed·UUniversity of Arkansas·Phase 2·NCT00083382·83 enrolled

Sclerosing Cholangitis1 trial

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Terminated·MMayo Clinic·Phase 2·NCT00953615·1 enrolled

AL amyloidosis1 trial

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Unknown status·GGuangdong Provincial People's Hospital·Phase 4·NCT04612582·70 enrolled

Metastatic Head and Neck Cancer1 trial

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003850·47 enrolled

Discoid Lupus Erythematosus1 trial

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001680·17 enrolled

Myeloma1 trial

IFM 99-02 Thalidomide in Myeloma

Completed·UUniversity Hospital, Toulouse·Phase 3·NCT00222053·800 enrolled

Systemic Sclerosis1 trial

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Terminated·NNYU Langone Health·Phase 1·NCT00418132·30 enrolled

HIV infection1 trial

Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004276·50 enrolled

Endometrial Cancer1 trial

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025467·60 enrolled

Celecoxib1 trial

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Completed·—·Phase 2·NCT00357500·101 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Terminated·MM.D. Anderson Cancer Center·N/A·NCT01927718·10 enrolled

Maintenance Treatment1 trial

Thalidomide Maintenance Treatment in DLBCL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03016000·226 enrolled

Leukemia1 trial

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

Completed·UUniversity of Arkansas·Phase 2·NCT00083694·25 enrolled

COVID-191 trial

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19

Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT04273581·40 enrolled

Treatment1 trial

Phase II Study Using Thalidomide for the Treatment of ALS

Completed·—·Phase 2·NCT00140452·24 enrolled

Thyroid Cancer1 trial

Thalidomide in Treating Patients With Thyroid Cancer

Completed·KKenneth Ain·Phase 2·NCT00026533

Autoimmune Disease1 trial

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03122431·93 enrolled

Temozolomide1 trial

Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00006358·44 enrolled

Systemic Mastocytosis1 trial

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Completed·—··NCT00769587

Ovarian Epithelial Cancer1 trial

Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer

Completed·CCancer Research UK·Phase 2·NCT00004876·30 enrolled

Fallopian Tube Cancer1 trial

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00041080·139 enrolled

Adrenoleukodystrophy1 trial

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004450·60 enrolled

Injury1 trial

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

Not yet recruiting·YYongquan Shi·Phase 2·NCT06617182·150 enrolled

Aphthous Ulcer1 trial

Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000790·164 enrolled

Adenocarcinoma1 trial

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00083005·60 enrolled

Sarcoidosis1 trial

SARCOTHAL. Thalidomide in Skin Sarcoidosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00305552·40 enrolled

Congestive Heart Failure1 trial

THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01640639·100 enrolled

Metastatic Prostate Cancer1 trial

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00020046

Malignant Glioma1 trial

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

Completed·WWake Forest University Health Sciences·Phase 2·NCT00079092·18 enrolled

Ankylosing Spondylitis1 trial

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Completed·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 2·NCT02201043·197 enrolled

Survival1 trial

Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Completed·SShanghai Zhongshan Hospital··NCT07321613·545 enrolled

Relapsed/Refractory1 trial

Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

Active, not recruiting·—·Phase 2·NCT07204041·40 enrolled

Camrelizumab1 trial

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Unknown status·HHenan Cancer Hospital·Phase 2·NCT06231680·132 enrolled

Stomatitis1 trial

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

Terminated·NNational Institute of Nursing Research (NINR)·Phase 2·NCT00075023·10 enrolled

Amyotrophic Lateral Sclerosis1 trial

Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)

Terminated·—·Phase 2·NCT00231140·40 enrolled

Psoriasis1 trial

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

Completed·WWake Forest University·Phase 2·NCT01891019·21 enrolled

Immune Response1 trial

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

Completed·LLouisiana State University Health Sciences Center in New Orleans·N/A·NCT00002174·20 enrolled

Inflammatory Bowel Disease1 trial

Thalidomide in Pediatric Inflammatory Bowel Diseases.

Completed·IIRCCS Burlo Garofolo·Phase 3·NCT00720538·84 enrolled

Chronic Graft Versus Host Disease1 trial

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003894·36 enrolled

Pneumonia1 trial

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia

Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT04273529·100 enrolled

Colorectal Cancer1 trial

Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00310076·29 enrolled

EGFR Mutation1 trial

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03341494·128 enrolled

Metastatic Neuroendocrine Tumor1 trial

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027638

Anti-angiogenic Therapy1 trial

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

Completed·WWashington University School of Medicine·Phase 1·NCT01661400·14 enrolled

Newly Diagnosed1 trial

TCD Followed by autoSCT for Newly Diagnosed MM Patients

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00349115·43 enrolled

Small Cell Lung Cancer1 trial

Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·—·Phase 2·NCT00053300·30 enrolled

Pancreatic Neuroendocrine Tumor1 trial

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03204032·60 enrolled

Hematologic Cancer1 trial

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00009984·70 enrolled

Glioblastoma Multiforme1 trial

Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

Completed·—·Phase 2·NCT00039468·26 enrolled

Exercise1 trial

Effects of Exercise in Combination With Epoetin Alfa

Completed·UUniversity of Arkansas·N/A·NCT00577096·120 enrolled

Leiomyosarcoma1 trial

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00033709

Chronic Prostatitis1 trial

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Terminated·KKenneth Peters, MD·Phase 2·NCT00301405·9 enrolled

Ovarian Cancer1 trial

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00016224

Systemic Inflammatory Response Syndrome1 trial

The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

Terminated·—·Phase 3·NCT00529633·16 enrolled

Trial1 trial

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00871013·160 enrolled

Renal Cell Carcinoma1 trial

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Completed·SStanford University·Phase 2·NCT00226980·30 enrolled

Unspecified6 trials

Use of Thalidomide in Patients With Arachnoiditis

Completed·WWashington University School of Medicine·Phase 2·NCT00284505·3 enrolled

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 3·NCT00572169·177 enrolled

Blood and Marrow Transplant Clinical Research Network

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00023530

Show 3 more trials

Thalidomide Therapy for VEOIBD

Recruiting·—··NCT06382519·40 enrolled

The Therapeutic Effect of Thalidomide in RI

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT03208413·58 enrolled

The Effects of Thalidomide on Symptom Clusters

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00379353·32 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 16, 1998

THALOMID

NDA NDA020785

Feb 12, 1999

THALOMID

NDA NDA020785

May 28, 1999

THALOMID

NDA NDA020785

May 28, 1999

THALOMID

NDA NDA020785

Oct 28, 1999

THALOMID

NDA NDA020785

Oct 28, 1999

THALOMID

NDA NDA020785

Oct 28, 1999

THALOMID

NDA NDA020785

Oct 28, 1999

THALOMID

NDA NDA020785

Apr 3, 2000

THALOMID

NDA NDA020785

May 15, 2000

THALOMID

NDA NDA020785

Sep 4, 2001

THALOMID

NDA NDA020785

Sep 4, 2001

THALOMID

NDA NDA020785

Nov 1, 2001

THALOMID

NDA NDA020785

Nov 16, 2001

THALOMID

NDA NDA020785

Nov 16, 2001

THALOMID

NDA NDA020785

Jan 17, 2003

THALOMID

NDA NDA020785

Jan 17, 2003

THALOMID

NDA NDA020785

Oct 27, 2003

THALOMID

NDA NDA020785

Oct 27, 2003

THALOMID

NDA NDA020785

Oct 27, 2003

THALOMID

NDA NDA020785

Mar 5, 2004

THALOMID

NDA NDA020785

Mar 5, 2004

THALOMID

NDA NDA020785

May 25, 2006

THALOMID

NDA NDA020785

Jan 10, 2007

THALOMID

NDA NDA020785

Aug 3, 2010

THALOMID

NDA NDA020785

Feb 3, 2012

THALOMID

NDA NDA020785

Feb 3, 2012

THALOMID

NDA NDA020785

Feb 3, 2012

THALOMID

NDA NDA020785

Feb 8, 2013

THALOMID

NDA NDA020785

Nov 15, 2013

THALOMID

NDA NDA020785

Jun 19, 2014

THALOMID

NDA NDA020785

Sep 12, 2014

THALOMID

NDA NDA020785

Aug 5, 2015

THALOMID

NDA NDA020785

Sep 13, 2015

THALOMID

NDA NDA020785

Oct 27, 2015

THALOMID

NDA NDA020785

Dec 1, 2015

THALOMID

NDA NDA020785

Apr 22, 2016

THALOMID

NDA NDA020785

Jan 27, 2017

THALOMID

NDA NDA020785

Jun 27, 2017

THALOMID

NDA NDA020785

Nov 30, 2017

THALOMID

NDA NDA020785

Dec 29, 2017

THALOMID

NDA NDA020785

Jun 7, 2019

THALOMID

NDA NDA020785

Dec 4, 2019

THALOMID

NDA NDA020785

Feb 25, 2021

THALOMID

NDA NDA020785

Aug 5, 2021

THALOMID

NDA NDA020785

Mar 24, 2023

THALOMID

NDA NDA020785

Apr 27, 2026

THALOMID

NDA NDA020785

Sources

References

[1]
ClinicalTrials.gov — 311 trial records for thalidomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Thalomid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — thalidomide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for thalidomide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020785). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Thalomid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Multiple Myeloma46 trials

Hepatocellular Carcinoma7 trials

Dexamethasone5 trials

Lymphoma4 trials

Thalassemia4 trials

Prostate Cancer4 trials

Vascular Malformation4 trials

Liver Cancer3 trials

Metastatic Melanoma3 trials

Non-Small Cell Lung Cancer3 trials

Efficacy and Safety3 trials

Metastatic Colorectal Cancer2 trials

Glioma2 trials

Waldenstrom macroglobulinemia2 trials

Patients With Advanced Solid Tumors2 trials

Idiopathic Pulmonary Fibrosis2 trials

Radiation Therapy2 trials

Maintenance Therapy2 trials

Crohn's Disease2 trials

Mantle Cell Lymphoma2 trials

Myelofibrosis2 trials

Beta-Thalassemia2 trials

HIV wasting syndrome2 trials

Myelodysplastic Syndrome2 trials

Chronic Lymphocytic Leukemia2 trials

Macroglobulinemia2 trials

Primary Systemic Amyloidosis2 trials

Myelodysplastic Syndromes2 trials

Plasma Cell Leukemia1 trial

Nausea and vomiting1 trial

Cirrhosis1 trial

NSCLC1 trial

Hepatocellular Cancer1 trial

Oral1 trial

Esophageal Cancer1 trial

Safety and Efficacy1 trial

Soft Tissue Sarcoma1 trial

Malnutrition1 trial

Transplantation1 trial

Venous malformation1 trial

Advanced NSCLC1 trial

Proctitis1 trial

Recurrent1 trial

Amyloidosis1 trial

Ovarian Reserve1 trial

Carcinosarcoma1 trial

Angiogenesis1 trial

Sclerosing Cholangitis1 trial

AL amyloidosis1 trial

Metastatic Head and Neck Cancer1 trial

Discoid Lupus Erythematosus1 trial

Myeloma1 trial

Systemic Sclerosis1 trial

HIV infection1 trial

Endometrial Cancer1 trial

Celecoxib1 trial

Autologous Hematopoietic Stem Cell Transplantation1 trial

Maintenance Treatment1 trial

Leukemia1 trial

COVID-191 trial

Treatment1 trial

Thyroid Cancer1 trial

Autoimmune Disease1 trial

Temozolomide1 trial

Systemic Mastocytosis1 trial

Ovarian Epithelial Cancer1 trial

Fallopian Tube Cancer1 trial

Adrenoleukodystrophy1 trial

Injury1 trial

Aphthous Ulcer1 trial

Adenocarcinoma1 trial

Sarcoidosis1 trial